PE20050052A1 - Un nuevo proceso para la preparacion de derivados de epotilona, nuevos derivados de epotilona, asi como nuevos productos intermediarios para el proceso - Google Patents

Un nuevo proceso para la preparacion de derivados de epotilona, nuevos derivados de epotilona, asi como nuevos productos intermediarios para el proceso

Info

Publication number
PE20050052A1
PE20050052A1 PE2003000922A PE2003000922A PE20050052A1 PE 20050052 A1 PE20050052 A1 PE 20050052A1 PE 2003000922 A PE2003000922 A PE 2003000922A PE 2003000922 A PE2003000922 A PE 2003000922A PE 20050052 A1 PE20050052 A1 PE 20050052A1
Authority
PE
Peru
Prior art keywords
new
methyl
epotilone
derivatives
dimethyl
Prior art date
Application number
PE2003000922A
Other languages
English (en)
Spanish (es)
Inventor
Guido Koch
Olivier Loiseleur
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050052A1 publication Critical patent/PE20050052A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2003000922A 2002-09-13 2003-09-11 Un nuevo proceso para la preparacion de derivados de epotilona, nuevos derivados de epotilona, asi como nuevos productos intermediarios para el proceso PE20050052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0221312.2A GB0221312D0 (en) 2002-09-13 2002-09-13 Organic compounds

Publications (1)

Publication Number Publication Date
PE20050052A1 true PE20050052A1 (es) 2005-03-28

Family

ID=9944042

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000922A PE20050052A1 (es) 2002-09-13 2003-09-11 Un nuevo proceso para la preparacion de derivados de epotilona, nuevos derivados de epotilona, asi como nuevos productos intermediarios para el proceso

Country Status (29)

Country Link
US (1) US7470792B2 (enExample)
EP (1) EP1539768B1 (enExample)
JP (1) JP4628102B2 (enExample)
KR (1) KR20050042500A (enExample)
CN (1) CN100522968C (enExample)
AR (1) AR041231A1 (enExample)
AT (1) ATE373663T1 (enExample)
AU (2) AU2003267349B2 (enExample)
BR (1) BR0314263A (enExample)
CA (1) CA2497119C (enExample)
CY (1) CY1107794T1 (enExample)
DE (1) DE60316456T2 (enExample)
DK (1) DK1539768T3 (enExample)
EC (1) ECSP055652A (enExample)
ES (1) ES2290489T3 (enExample)
GB (1) GB0221312D0 (enExample)
IL (1) IL166829A (enExample)
MX (1) MXPA05002785A (enExample)
MY (1) MY140442A (enExample)
NO (1) NO20051794L (enExample)
NZ (1) NZ538612A (enExample)
PE (1) PE20050052A1 (enExample)
PL (1) PL375039A1 (enExample)
PT (1) PT1539768E (enExample)
RU (2) RU2343155C2 (enExample)
SG (1) SG155770A1 (enExample)
TW (1) TWI289563B (enExample)
WO (1) WO2004024735A2 (enExample)
ZA (1) ZA200501008B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716610B2 (en) * 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
NZ337195A (en) * 1997-02-25 2001-05-25 Biotechnolog Forschung Gmbh Epothilones with a modified side chain
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
ES2207983T3 (es) * 1998-12-22 2004-06-01 Novartis Ag Derivados de epotilona y su uso como agentes antitumorales.
AU6233600A (en) * 1999-07-22 2001-02-13 Schering Aktiengesellschaft Process for the production of epothiolone b and derivatives as well as intermediate products for this process
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2425828A1 (en) * 2000-10-13 2002-04-18 The University Of Mississippi Synthesis of epothilones and related analogs
IL166039A0 (en) * 2002-07-31 2006-01-15 Schering Ag New effector conjugates process for their production and their pharmaceutical use

Also Published As

Publication number Publication date
AR041231A1 (es) 2005-05-11
RU2005110925A (ru) 2006-01-20
TW200413388A (en) 2004-08-01
AU2003267349B2 (en) 2008-05-01
NO20051794D0 (no) 2005-04-12
GB0221312D0 (en) 2002-10-23
DK1539768T3 (da) 2008-01-07
KR20050042500A (ko) 2005-05-09
CN100522968C (zh) 2009-08-05
BR0314263A (pt) 2005-07-05
ZA200501008B (en) 2006-12-27
RU2008129613A (ru) 2010-01-27
IL166829A (en) 2011-01-31
PT1539768E (pt) 2007-12-17
US7470792B2 (en) 2008-12-30
SG155770A1 (en) 2009-10-29
ECSP055652A (es) 2005-05-30
EP1539768B1 (en) 2007-09-19
CA2497119A1 (en) 2004-03-25
DE60316456T2 (de) 2008-06-19
CY1107794T1 (el) 2013-06-19
NZ538612A (en) 2008-01-31
CA2497119C (en) 2011-08-02
TWI289563B (en) 2007-11-11
AU2008203451A1 (en) 2008-08-21
PL375039A1 (en) 2005-11-14
WO2004024735A3 (en) 2004-07-22
JP2006511469A (ja) 2006-04-06
JP4628102B2 (ja) 2011-02-09
ES2290489T3 (es) 2008-02-16
EP1539768A2 (en) 2005-06-15
MXPA05002785A (es) 2005-06-03
MY140442A (en) 2009-12-31
NO20051794L (no) 2005-04-12
WO2004024735A2 (en) 2004-03-25
RU2404985C2 (ru) 2010-11-27
ATE373663T1 (de) 2007-10-15
DE60316456D1 (de) 2007-10-31
HK1078853A1 (en) 2006-03-24
RU2343155C2 (ru) 2009-01-10
CN1681824A (zh) 2005-10-12
AU2003267349A1 (en) 2004-04-30
US20060106073A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
PE20030612A1 (es) Benzoimidazoles
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20001464A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos
AR022230A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
PE20021006A1 (es) Derivados de 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la proteinquinasa
ES2314418T3 (es) Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias.
PA8591701A1 (es) Derivados de pirrolopirimidina
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
SG171471A1 (en) New benzimidazole derivatives
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
NO20044041L (no) Okso-azabisykliske forbindelser
AR017904A1 (es) Mezclas fungicidas y procedimentos para controlar hongos nocivos que las emplean.
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
PE20050052A1 (es) Un nuevo proceso para la preparacion de derivados de epotilona, nuevos derivados de epotilona, asi como nuevos productos intermediarios para el proceso
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
EA200500133A1 (ru) Производные пирролидина в качестве антагонистов окситоцина
PE20050440A1 (es) Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas
UA92195C2 (ru) Оптически активные карбаматы, способ их получения и их применение в качестве фармацевтических промежуточных соединений
DK1531158T3 (da) Lipid A topisk, især kosmetisk, sammensætning, der omfatter det

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed